Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments

Abstract

Chronic myeloid leukemia (CML) is characterized by the accumulation of active BCR-ABL protein. Imatinib is the first-line treatment of CML; however, many patients are resistant to this drug. In this study, we aimed to compare the differences in expression patterns and functions of time-series genes in imatinib-resistant CML cells under different drug treatments. GSE24946 was downloaded from the GEO database, which included 17 samples of K562-r cells with (n=12) or without drug administration (n=5). Three drug treatment groups were considered for this study: arsenic trioxide (ATO), AMN107, and ATO+AMN107. Each group had one sample at each time point (3, 12, 24, and 48 h). Time-series genes with a ratio of standard deviation/average (coefficient of variation) >0.15 were screened, and their expression patterns were revealed based on Short Time-series Expression Miner (STEM). Then, the functional enrichment analysis of time-series genes in each group was performed using DAVID, and the genes enriched in the top ten functional categories were extracted to detect their expression patterns. Different time-series genes were identified in the three groups, and most of them were enriched in the ribosome and oxidative phosphorylation pathways. Time-series genes in the three treatment groups had different expression patterns and functions. Time-series genes in the ATO group (e.g. CCNA2 and DAB2) were significantly associated with cell adhesion, those in the AMN107 group were related to cellular carbohydrate metabolic process, while those in the ATO+AMN107 group (e.g. AP2M1) were significantly related to cell proliferation and antigen processing. In imatinib-resistant CML cells, ATO could influence genes related to cell adhesion, AMN107 might affect genes involved in cellular carbohydrate metabolism, and the combination therapy might regulate genes involved in cell proliferation.

References

[1] Adamia S, Pilarski PM, Bar-Natan M, et al. Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Current Cancer Drug Targets, 2013,13(7):735–748

[2] CortesJE, KimDW, KantarjianHM, et al.. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. Br J Haematol, 2015, 168(1): 69-81

[3] HöglundM, SandinF, SimonssonB. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol, 2015, 94(2): 241-247

[4] AnX, TiwariAK, SunY, et al.. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk Res, 2010, 34(10): 1255-1268

[5] ShahNP, KimDW, KantarjianH, et al.. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica, 2010, 95(2): 232-240

[6] KantarjianHM, ShahNP, CortesJE, et al.. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012, 119(5): 1123-1129

[7] le CoutreP, OttmannOG, GilesF, et al.. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 2008, 111(4): 1834-1839

[8] NakaK, HoshiiT, HiraoA. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci, 2010, 101(7): 1577-1581

[9] XiaY, FangH, ZhangJ, et al.. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Haywood), 2013, 238(8): 932-942

[10] WangW, LvFF, DuY, et al.. The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis. Cancer Cell International, 2015, 15(1): 1-8

[11] FujitaA, SatoJR, Garay-MalpartidaHM, et al.. Modeling nonlinear gene regulatory networks from time series gene expression data. J Bioinform Comput Biol, 2008, 6(5): 961-979

[12] KnezevicSZ, StreibigJC, RitzC. Utilizing R software package for dose-response studies: The concept and data analysis. Weed Technol, 2007, 21(3): 840-848

[13] GhandhiSA, SinhaA, MarkatouM, et al.. Time-series clustering of gene expression in irradiated and bystander fibroblasts: an application of FBPA clustering. BMC Genomics, 2011, 12: 2

[14] DennisG, ShermanBT, HosackDA, et al.. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol, 2003, 4(5): P3

[15] BenjaminiY, HochbergY. Controlling the false discovery rate -a practical and powerful approach to multiple testing. J Roy Stat Soc B Met, 1995, 57(1): 289-300

[16] ErnstJ, Bar-JosephZ. STEM: a tool for the analysis of short time series gene expression data. BMC Bioinformatics, 2006, 7: 191

[17] HarrisMA, ClarkJ, IrelandA, et al.. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res, 2004, 32: D258-261

[18] BrunsI, CzibereA, FischerJC, et al.. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia, 2009, 23(5): 892-899

[19] WangB, LiD, KovalchukA, et al.. Ionizing radiation-inducible miR-27b suppresses leukemia proliferation via targeting cyclin A2. Int J Radiat Oncol Biol Phys, 2014, 90(1): 53-62

[20] ZhangQY, MaoJH, LiuP, et al.. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A, 2009, 106(9): 3378-3383

[21] ChoRJ, HuangM, CampbellMJ, et al.. Transcriptional regulation and function during the human cell cycle. Nat Genet, 2001, 27(1): 48-54

[22] ZhuX, OhtsuboM, BöhmerRM, et al.. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol, 1996, 133(2): 391-403

[23] CadwaladerEL, CondicML, YostHJ. 2-O-sulfotransferase regulates Wnt signaling, cell adhesion and cell cycle during zebrafish epiboly. Development, 2012, 139(7): 1296-1305

[24] El EitRM, IskandaraniAN, SalibaJL, et al.. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. Int J Cancer, 2014, 134(4): 988-996

[25] NakaK, HoshiiT, MuraguchiT, et al.. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature, 2010, 463(7281): 676-680

[26] ParsonsJT, HorwitzAR, SchwartzMA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Molecul Cell Biol, 2010, 11(9): 633-643

[27] CheongSM, ChoiH, HongBS, et al.. Dab2 is pivotal for endothelial cell migration by mediating VEGF expression in cancer cells. Exp Cell Res, 2012, 318(5): 550-557

[28] HuangXD, WangZF, DaiLM, et al.. Microarray analysis of the hypoxia-induced gene expression profile in malignant C6 glioma cells. Asian Pac J Cancer Prev, 2012, 13(9): 4793-4799

[29] GolemovicM, VerstovsekS, GilesF, et al.. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res, 2005, 11(13): 4941-4947

[30] SureshS, MccallumL, CrawfordLJ, et al.. The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia. J Pathol, 2013, 231(3): 378-387

[31] TalpazM, HehlmannR, Quintás-CardamaA, et al.. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia, 2013, 27(4): 803-812

[32] HuW, YenYT, SinghS, et al.. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol, 2012, 25(4): 277-288

[33] BaiY, ZhengJ, WangN, et al.. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy. J Huazhong Univ Sci Technol Med Sci, 2015, 35(5): 689-693

[34] BrownS, HutchinsonCV, Aspinall-O’DeaM, et al.. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein. Eur J Haematol, 2014, 93(2): 96-102

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology and Springer-Verlag GmbH Germany